NCT02046174已完成2 期
A Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 7
- 主要终点
- Overall Survival
研究概览
简要总结
This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for patients with advanced colorectal cancer that no longer responds to standard therapies.
The treatment is being evaluated for its effect on tumor growth. It consists of the placement (implantation) of small beads that contain mouse renal adenocarcinoma cells (RENCA macrobeads). The cells in the macrobeads produce substances that have been shown to slow or stop the growth of tumors in experimental animals and veterinary patients. It has been tested in 31 human subjects with different types of cancers in a Phase I safety trial. Phase II studies in patients with colorectal, pancreatic or prostate cancers are in progress
详细描述
This is a Phase IIb, multicenter, nonrandomized, open-label study with RENCA macrobeads in patients with treatment-resistant, metastatic colorectal carcinoma to determine the effect of RENCA macrobead implantation on overall survival compared with best supportive care.
Two treatment groups will be enrolled in this study, as follows:
- Group A (n=40) - patients who will undergo up to 4 implantations of RENCA macrobeads (no less than 3 months apart), at a dosage level of 8 RENCA macrobeads per kilogram of body weight
- Group B (n=80) - patients who had previously decided (independently of this study) to receive, or continue receiving, best supportive care, defined as management of symptoms aimed at maintaining or improving quality of life, but not including approved therapies targeting the patient's malignancy
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients in both treatment groups must meet all of the following criteria to be considered eligible to participate in the study:
- •Adult men or women, aged 18 years or older, with histologically-confirmed, metastatic adenocarcinoma of the colon or rectum that has been proven to be resistant to available treatment options, including at least 2 such options from available chemotherapy, targeted, and/or other regimens.
- •Radiographic evidence of disease progression.
- •Life expectancy of at least 6 weeks, in the investigator's opinion, at the time disease progression is documented.
- •Considered surgical candidates on the basis of co-morbidity risks, number and sites of metastases, and ability to undergo general anesthesia.
- •Able to understand the risks of experimental therapy and provide written consent by signing the appropriate form.
- •Patients in Group A must also meet all of the following additional criteria:
- •ECOG performance status score of 0, 1, or
- •Adequate hematologic function, defined as follows:
- •absolute neutrophil count (ANC) ≥1500 /mL
- •hemoglobin ≥9 g/dL
- •platelets ≥75,000 /mL
- •Adequate hepatic function, defined as follows:
- •bilirubin ≤1.5 times the upper limit of normal (x ULN)
- •aspartate transaminase (AST) ≤3 x ULN, or ≤5 x ULN if liver metastases are present
- •alanine transaminase (ALT) ≤3, x ULN, or ≤5 x ULN if liver metastases are present
- •Adequate renal function, defined as creatinine ≤2.0 mg/dL.
- •Adequate coagulation function, defined as follows:
- •International Normalized Ratio (INR) ≤1.5 or between 2 and 3 if the patient is receiving anticoagulation
- •Partial Thromboplastin Time (PTT) ≤5 seconds above the ULN Note: Patients receiving full-dose anticoagulation therapy must have received a stable dose of oral anticoagulant therapy or low-molecular-weight heparin.
- •Clinically significant toxic effects of chemotherapy (excluding alopecia), radiotherapy, hormonal therapy, or prior surgery must have resolved to Grade 1 or better, with the exception of peripheral neuropathy, which must have resolved to Grade 2 or better.
- •Female participants of childbearing potential must have had a negative serum pregnancy test at screening; and must also agree to contraceptive use while on study if sexually active. Male subjects and their partners must have agreed to use condoms.
排除标准
- •Patients in either treatment group who meet any of the following criteria will be excluded from participating in the study:
- •Hepatic blood flow abnormalities, i.e., portal vein hypertension and thrombosis, and/or a large volume of ascites.
- •Concurrent cancer of any other type, except skin cancers other than melanoma.
- •A positive test result for HIV or any hepatitis other than A at screening.
- •Considered by the investigator to be unsuitable for participation in the study upon review of medical history, physical examination, or clinical laboratory test results.
- •Patients in Group A who meet any of the following criteria will be excluded from participating in the study:
- •Received FDA-approved chemotherapy within 3 weeks of Day 0, or bevacizumab (or similar drugs) within 4 weeks of Day 0, or radiation therapy at any site within 4 weeks of Day
- •Investigational anticancer therapy within 4 weeks of Day
- •Positive reaction to the skin test for allergy to mouse antigen.
- •History of hypersensitivity reaction that, in the opinion of the investigator, poses an increased risk of an allergic reaction to the RENCA macrobeads, particularly any known allergy to murine antigens or body tissues.
- •Ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmias (with the exception of well controlled atrial fibrillation), active bleeding, or psychiatric illness, or social situations that could interfere with the patient's ability to participate in the study.
结局指标
主要结局
Overall Survival
时间窗: From date of the most recent scan prior to the first macrobead implantation; assessed up to 32 months.
The primary objective of this study was to evaluate the efficacy of RENCA macrobead implantation as assessed by overall survival in subjects with treatment-resistant mCRC.
次要结局
- Emotional Function(Baseline; Day 14, 30, 60 post-Implant 1; Day 14, 30, 60 post-Implant 2)
- Global Health Status(Baseline; Day 14, 30, 60 post-Implant 1; Day 14, 30, 60 post-Implant 2)
- Performance Status (ECOG Score)(Baseline; Day 14, 30, 60 post-Implant 1; Day 14, 30, 60 post-Implant 2)
- Role Function(Baseline; Day 14, 30, 60 post-Implant 1; Day 14, 30, 60 post-Implant 2)
- Pain Assessment(Baseline; Day 14, 30, 60 post-Implant 1; Day 14, 30, 60 post-Implant 2)
- Activities of Daily Living (KPS Score)(Baseline; Day 14, 30, 60 post-Implant 1; Day 14, 30, 60 post-Implant 2)
- Physical Function(Baseline; Day 14, 30, 60 post-Implant 1; Day 14, 30, 60 post-Implant 2)
- Cognitive Function(Baseline; Day 14, 30, 60 post-Implant 1; Day 14, 30, 60 post-Implant 2)
- Social Function(Baseline; Day 14, 30, 60 post-Implant 1; Day 14, 30, 60 post-Implant 2)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-TProstate CancerNCT01174368The Rogosin Institute1
已完成
2 期
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal CancerPancreatic Adenocarcinoma Non-resectablePancreatic Adenocarcinoma MetastaticColorectal Cancer MetastaticNCT01053013The Rogosin Institute58
已完成
2 期
A clinical study to see the effect of ArtemiC in patients with COVID-19CTRI/2021/02/031520MGC Pharmaceuticals Ltd20
招募中
2 期
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II TrialMarginal Zone Lymphoma(MZL)NCT06700798Fei Li90
进行中（未招募）
不适用
Experimental study in humans to evaluate the efficacy and safety of blood products rich in proteins for the treatment of anal fistulas in Crohn's patients without subsidiary drug treatment.Perianal fistulas in Crohn's Disease PatientsMedDRA version: 14.1Level: PTClassification code 10002156Term: Anal fistulaSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-006127-38-ESFundación FISEVI